ASCO 2017: What’s New in (neo)adjuvant Breast Cancer Treatment?

Speaker: Sofia Braga

Sofia Braga discusses the results from 3 trials presented at ASCO 2017 that evaluated the role, duration and a combination of adjuvant therapy drugs (dual inhibition) in patients with HER2-positive early breast cancer.

Sofia Braga discusses the results from 3 trials presented at ASCO 2017 that evaluated the role, duration and a combination of adjuvant therapy drugs (dual inhibition) in patients with HER2-positive early breast cancer.

Abstracts as referenced in the ASCO 2017 programme

  • LBA500: APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).
  • 501: 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.
  • 502: Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.